Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.3 (market cap $60.06B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.91 (market cap $1.36B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 44.2× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 6 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| TAK | USAS | |
|---|---|---|
Market Cap | $60.06B | $1.36B |
Volume | 2,925,042 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $19.05 | $10.03 |
52-Week Low | $13.23 | $3.59 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $87.89B | $1.29B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.
Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
